

ABSTRACT

Background: Efficacy and safety data of novel antiretrovirals, such as dolutegravir (DTG), in children and adolescents, often lags behind adult data, and can lead to hesitation and slow uptake by HIV clinicians. Beginning in 2019, the Baylor Tanzania programme began an enthusiastic rollout of DTG among CALHIV. We describe outcomes and safety data of this DTG rollout among CALHIV enrolled at the Baylor Tanzania clinics in Mbeya and Mwanza, Tanzania. **Methods:** Retrospective chart review was conducted to describe outcomes and safety data of CALHIV who received DTG as part of their ART at the Baylor College of Medicine Children's Foundation - Tanzania Centres of...